Bayer's Nexavar disappoints in breast cancer

Share this article:

Bayer and Amgen clocked another failed indication-expansion effort for the cancer drug Nexavar. The companies announced Friday the drug did not hit its Phase-III primary target of improving progression-free survival among patients receiving both Nexavar and chemotherapy. The RESILIENCE study focused on patients with HER2-negative breast cancer who are resistant to, or failed on, taxane therapy or who have failed on anthracycline or for whom anthracycline is not indicated.

The companies also had a setback in March when they announced Nexavar failed to hit the Phase-III target of recurrence-free survival among liver-cancer patients when used as an adjuvant therapy.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.